Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $11K rose 120.0% year over year, ahead of the -31.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 10.0% from the prior quarter. Over 3 fiscal years it compounded at -31.1% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +120.0% holds above the trailing-twelve-month pace of -31.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 36K USD
- Year-over-year change
- +125.0%
- 3-year CAGR
- -31.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36K | +125.0% |
| FY2024 | 2024-12-31 | 16K | -83.5% |
| FY2023 | 2023-12-31 | 97K | -11.8% |
| FY2022 | 2022-12-31 | 110K | — |
Depreciation & Amortization vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's LTM Mar 2026 depreciation & amortization of $42K is the lowest of the 11 companies compared; the peer median is $2.96M.
- Its year-over-year change of -31.1% is the 10th highest of 11, against a peer median of -8.2%.
- Over three fiscal years its annual growth of -31.1% compares with a peer median of +19.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.54M | -16.0% | -1.1% | 3350.2% | |
| LTM Mar 2026 | $6.32M | -43.5% | +23.7% | — | |
| LTM Mar 2026 | $4.93M | +55.9% | +19.6% | 7.1% | |
| LTM Mar 2026 | $4.42M | +82.7% | +85.3% | 31.9% | |
| LTM Mar 2026 | $3.13M | -28.6% | +0.0% | 27.9% | |
| LTM Mar 2026 | $2.79M | -10.3% | +0.1% | 9.9% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $262.3K | +45.1% | +30.9% | — |
| LTM Mar 2026 | $226K | -16.3% | +27.5% | 383.1% | |
| LTM Mar 2026 | $122K | -6.2% | -36.3% | 0.2% | |
ZURAZura Bio Limited | LTM Mar 2026 | $56K | +211.1% | — | — |
| LTM Mar 2026 | $42K | -31.1% | -31.1% | — | |
| Peer median (excluding AARD) | $2.96M | -8.2% | +19.6% | 27.9% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 7.17M | 4.48M | 17.36M | 48.94M |
| Selling, General & Admin | 2.7M | 2.17M | 5.31M | 13.79M |
| Operating Expenses | 11.36M | 7.42M | 22.79M | 62.73M |
| Depreciation & Amortization | 110K | 97K | 16K | 36K |
| EBITDA | (10.76M) | (6.56M) | (22.65M) | (57.56M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (11.36M) | (7.42M) | (22.79M) | (62.73M) |
| Operating Margin | — | — | — | — |
| Interest Income | 120K | 1.42M | 2.41M | 5.14M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (2.2M) | 207K | 2.2M | 5.13M |
| Income Before Tax | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.63) | (0.34) | (0.95) | (2.64) |
| EPS (Diluted) | (0.63) | (0.34) | (0.95) | (2.64) |
| Weighted Avg Shares | 21.38M | 21.38M | 21.7M | 21.82M |
| Weighted Avg Shares (Diluted) | 21.38M | 21.38M | 21.7M | 21.82M |
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.